HISTORIXNCT05575024
Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 2 words Show 4 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Jun 30, 2026 to Dec 26, 2025
- Study completion date changed from estimate of Dec 31, 2026 to Dec 31, 2025
- Site details revised
- Notable Primary completion date: Oct 31, 2024 to Jun 30, 2026
- Study completion date: Dec 31, 2024 to Dec 31, 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Notable Start date: Jul 1, 2023 to Jan 1, 2024v5
- Notable Start date: Feb 1, 2023 to Jul 1, 2023v4
Show 2 earlier versionsHide 2 earlier versions
- Notable Start date: Dec 1, 2022 to Feb 1, 2023v3
- Notable Eligibility criteria revised
- Primary endpoints revised (2)
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Rate of all-cause mortality
Timeframe: 28 days
Occurrence rates of ventricular tachycardia, intradialytic hypotension
Timeframe: 28 days
Arms and interventions
Septic AKI
Patients with septic acute kidney injury requiring continuous renal replacement therapy
Devices: oXiris membrane, Polysulfone membrane
Sites
1 site in 1 country
- Seoul National University HospitalSeoul, South Korea